Clinical trials: Graft Patency, active
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Graft-versus-host Disease
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can…
- Trial name
- NCT06682169
- Testing
- Rovadicitinib, Imatinib, Methotrexate
- Where
- 41 sites in China
- Volunteers
- 182 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Gingival Recession, Generalized
Palatal Wound Healing After Free Gingival Graft Harvest in Diabetic Patients: A Clinical Trial
The goal of this clinical trial is to evaluate local and systemic factors involved in palatal mucosal healing after Free Gingival Graft harvest in diabetic patients and to compare them with those in non-diabetic patients.
- Conditions
- Diabetes Mellitus, Gingival Recession, Generalized, Gingival Recession, Localized
- Trial name
- NCT07500935
- Testing
- Free gingival graft
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mauro Santamaria
GVHD, Chronic
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2.
- Trial name
- NCT06169722
- Testing
- TDI01 suspension
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345624
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 80 people
- Sponsor
- Qing-Lei Zeng
Graft Vs Host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the…
- Trial name
- NCT05621759
- Testing
- Cyclophosphamide, Abatacept, Tacrolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Graft -Versus-host-disease, aGVHD
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
- Trial name
- NCT07246031
- Testing
- BPC-2001
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- BioPhoenix Co., Ltd.
Coronary Artery Disease, Coronary Artery Bypass Grafting
Total Arterial vs. Mixed Grafting in Left Coronary CABG
This is a prospective, randomized, double-blind controlled trial comparing the clinical efficacy of total arterial grafting (internal thoracic artery and radial artery) versus conventional mixed grafting (internal thoracic artery…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Arterial Graft, Graft Patency
- Trial name
- NCT07057713
- Testing
- Total Arterial Grafting, Conventional Mixed Grafting
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Hospital of Jilin University
Coronary Artery Disease
Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery
Internal thoracic arteries can be harvested in skeletonized or pedicled technique. Latest research has posed a potential adverse effect of skeletonizing the internal thoracic arteries on graft patency rates and clinical outcome.
- Trial name
- HARVITA (NCT05931783)
- Testing
- skeletonized harvesting technique, pedicled harvesting technique
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 1,350 people
- Sponsor
- Medical University Innsbruck
Graft -Versus-host-disease
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.
- Trial name
- ABRAXAS (NCT07808112)
- Testing
- Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Medical College of Wisconsin
Chronic Graft-versus-host-disease
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
- Trial name
- NCT06388564
- Testing
- Axatilimab, Ruxolitinib, Corticosteroids
- Where
- 68 sites in United States, Belgium and 5 more
- Volunteers
- 130 people
- Sponsor
- Incyte Corporation
Antibody-mediated Rejection
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
This multi-center study is an investigator-driven randomized controlled parallel group open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody tocilizumab (TCZ) to the standard of care (SOC)…
- Trial name
- INTERCEPT (NCT04561986)
- Testing
- Tocilizumab
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 50 people
- Sponsor
- Vastra Gotaland Region
Transfusion Dependent Thalassemia
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor…
- Trial name
- NCT06657391
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- Rongrong Liu
Graft Patency
Study of Feasibility for Surgical Patients Undergoing Heart Surgery With the Mammary Arteries: Reviewing Infection, Occlusion Rates and Pain Assessments.
The Pilot study for the COMFORT Trial is a single centre trial to determine the feasibility of the full COMFORT Trial. The main COMFORT Trial will be a multi-centre trial to investigate the coronary artery bypass grafting…
- Trial name
- COMFORT pilot (NCT07599553)
- Testing
- Skeletonized vs non-skeletonized harvesting of the left internal mammary artery
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Aortobifemoral Bypass, Aortoiliac Occlusive Disease
Norwegian Laparoscopic Aortic Surgery Trial
Patients with severe atherosclerotic occlusive disease can be operated on with an aortobifemoral bypass(ABFB)through a median laparotomy. Since 1993, this operation has also been performed laparoscopically.
- Conditions
- Aortobifemoral Bypass, Aortoiliac Occlusive Disease, TASC Type D Lesions, Laparoscopic Versus Open Bifurcation Graft
- Trial name
- NLAST (NCT01793662)
- Testing
- Laparoscopic aortobifemoral bypass
- Where
- Norway
- Volunteers
- 126 people
- Sponsor
- Oslo University Hospital
Dupuytren's Disease
Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease
Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand.
- Trial name
- REMEDY (NCT05067764)
- Testing
- Aponeurectomy with grafting, Aponeurectomy alone
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- Elsan
Acute Coronary Syndrome, Coronary Bypass Stenosis
Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)
The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary…
- Trial name
- NCT04783701
- Where
- 6 sites in Norway, Sweden
- Volunteers
- 360 people
- Sponsor
- University Hospital, Linkoeping
Chronic Graft-versus-host-disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT06263478
- Testing
- INCA034176
- Where
- 16 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Incyte Biosciences Japan GK
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Colorectal Cancer, Liver Metastases
The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases
To evaluate if the addition of liver transplantation primarily utilizing liver grafts from extended criteria donors not utilized for approved indications to conventional treatment of non-resectable/ non-abatable colorectal liver…
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Liver Metastases
- Trial name
- SOULMATE (NCT04161092)
- Testing
- Liver transplantation Ltx, Best alternative care
- Where
- 2 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Vastra Gotaland Region